KEFEA requests complete information regarding the investigation of the Pharmaceutical Services.

June 6, 2012

The recent findings made public from the comparative study prepared by the Pharmaceutical Services of the Ministry of Health for the pricing of drugs in Cyprus have caused great concern. The Cyprus Association of Pharmaceutical Research and Development Companies (KEFEA) has requested from the Ministry a copy of the investigation in order to study the results and form a position based on the complete picture and not just a few excerpts of the research findings. As the issue of pharmaceutical pricing is a serious one, KEFEA has also requested a meeting with Health Minister Stavros Malas.

KEFEA has publicly expressed its positions on the issue when it was called upon to attend the Parliamentary Health Committee and through announcements to the Press. KEFEA also delivered a document to the Minister of Health which analyzed its position on the pricing system in Cyprus, and presented specific suggestions for the conservation of resources in the health system.

KEFEA is engaging in a dialogue with the Ministry of Health and other relevant authorities in Cyprus, and is contributing in every possible way in the effort to create a better National Health System which will solve many of the problems facing the health sector in Cyprus today.

For more information please contact the KEFEA spokesperson at 99 457 225.


Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA)

The Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA) was founded in 2006 as the representative body of multinational pharmaceutical companies in Cyprus. Its members are GSK, Lilly, MSD, Novartis, Pfizer, Sanofi and Janssen, altogether employing more than 140 people in Cyprus. It is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). KEFEA’s mission is to provide Cypriots with quality healthcare and access to new medicines. Its objectives are to ensure uninterrupted access to medicines at reasonable prices in the Cyprus market, given the acknowledgement of budgetary constraints, provide scientific educational information on diseases and treatments to healthcare providers, ensure that European objectives regarding high healthcare standards are implemented in the Cyprus market, and comply with a common code of ethical practice.